Vascular Biogenics Ltd is a biotechnology business based in the US. Vascular Biogenics shares (VBLT) are listed on the NASDAQ and all prices are listed in US Dollars. Vascular Biogenics employs 41 staff and has a trailing 12-month revenue of around $572,000.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.17 |
|---|---|
| 52-week range | $0.15 - $2.54 |
| 50-day moving average | $0.21 |
| 200-day moving average | $1.23 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.47 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.17 from 2022-10-04
| 1 week (2022-09-28) | 6.92% |
|---|---|
| 1 month (2022-09-02) | -18.27% |
| 3 months (2022-07-05) | -90.23% |
| 6 months (2022-04-05) | -90.29% |
| 1 year (2021-10-05) | -91.63% |
|---|---|
| 2 years (2020-10-05) | -85.34% |
| 3 years (2019-10-04) | 1.28 |
| 5 years (2017-10-05) | 6.1 |
| Revenue TTM | $572,000 |
|---|---|
| Gross profit TTM | $403,000 |
| Return on assets TTM | -39.73% |
| Return on equity TTM | -80.04% |
| Profit margin | 0% |
| Book value | $0.50 |
| Market capitalisation | $11.1 million |
TTM: trailing 12 months
We're not expecting Vascular Biogenics to pay a dividend over the next 12 months.
Over the last 12 months, Vascular Biogenics's shares have ranged in value from as little as $0.145 up to $2.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vascular Biogenics's is 0.5605. This would suggest that Vascular Biogenics's shares are less volatile than average (for this exchange).
Vascular Biogenics Ltd. , a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.